Anticancer potential of nitric oxide (NO) in neuroblastoma treatment

Gordon, Jenna L.; Hinsen, Kristin J.; Reynolds, Melissa M.; Smith, Tyler A.; Tucker, Haley O.; Brown, Mark A.

doi:10.1039/d1ra00275a

Cited by 10 publications

(4 citation statements)

References 41 publications

(68 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Herein, the novel combination of NO, delivered via S-Nitrosoglutathione (GSNO) (Figure 1a), and SMYD3 inhibition, with inhibitor-4 (Figure 1b), is investigated for anticancer potential against breast cancers. In previous studies, the RSNO, GSNO, was shown to exhibit tumoricidal characteristics [30][31][32]. Likewise, a separate study indicated that a SYMD3 inhibitor, inhibitor-4, demonstrated potent impacts on two breast cancer lines, MCF7 and MDA-MB-231 (both lines linked to overexpression of SMYD3) [29].…”

Section: Introductionmentioning

confidence: 91%

Anticancer Impact of Nitric Oxide (NO) and NO Combination with SMYD-3 Inhibitor on Breast Carcinomas

et al. 2021

Self Cite

View full text Add to dashboard Cite

Despite enormous advances in the detection and treatment of breast cancer, it still remains the leading cancer diagnosis and has the second highest mortality rate. Thus, breast cancer research is a high priority for academics and clinicians alike. Based on previous research indicating the potential of nitric oxide (NO) and SMYD-3 inhibition, this work sought to expand upon these concepts and combine the two approaches. Both NO (from S-Nitrosoglutathione (GSNO)), termed Group 1, and a combination therapeutic, inhibitor-4 (SMYD-3 inhibitor) plus NO (from GSNO), termed Group 2, were evaluated for their efficacy on breast carcinoma cell lines MCF7 and MDA-MB-231, and the normal MCF10A breast cell line, using cellular viability, colony formation capacity, cytotoxicity, and cellular apoptosis analysis. These results indicated that, in Group 1, breast carcinoma lines MCF7 and MDA-MB-231, cells experienced a moderate reduction in cellular viability (~20–25%), a large reduction in colony formation capacity (~80–90%), a moderate increase in the relative number of dead cells, and a moderate increase in cellular apoptosis. Group 2 was significantly more impactful, with a ~50% knockdown in cellular viability, a 100% reduction in colony formation capacity, a large increase in the relative number of dead cells, and a large increase in cellular apoptosis. Additionally, Group 2 induced a very small impact on the normal MCF10A cell line. Cumulatively, this work revealed the exciting impact of this combination therapeutic, indicating its potential for clinical application and further research.

show abstract

Section: Introductionmentioning

confidence: 91%

Anticancer Impact of Nitric Oxide (NO) and NO Combination with SMYD-3 Inhibitor on Breast Carcinomas

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Nitric oxide ( • N = O, abbreviated NO), despite its structural simplicity, is an important free radical biomolecule with complex chemistry, which has a crucial role in several physiological and biological functions, e.g., the prevention of oxidative stress and cytokine activation, neurotransmission, and vascular homeostasis [ 1 ]. NO-based therapies exhibit great potential as antimicrobials and antivirals in the acceleration of wound healing and anticancer treatment [ 2 , 3 , 4 , 5 ]. More recently, the potential of inhaled NO was also explored in COVID-19 treatment, since it can stabilize oxidation stress, which is the major cause of comorbidity deaths [ 6 , 7 , 8 ].…”

Section: Introductionmentioning

confidence: 99%

Nanomolar Nitric Oxide Concentrations in Living Cells Measured by Means of Fluorescence Correlation Spectroscopy

et al. 2022

View full text Add to dashboard Cite

Measurement of the nitric oxide (NO) concentration in living cells in the physiological nanomolar range is crucial in understanding NO biochemical functions, as well as in characterizing the efficiency and kinetics of NO delivery by NO-releasing drugs. Here, we show that fluorescence correlation spectroscopy (FCS) is perfectly suited for these purposes, due to its sensitivity, selectivity, and spatial resolution. Using the fluorescent indicators, diaminofluoresceins (DAFs), and FCS, we measured the NO concentrations in NO-producing living human primary endothelial cells, as well as NO delivery kinetics, by an external NO donor to the immortal human epithelial living cells. Due to the high spatial resolution of FCS, the NO concentration in different parts of the cells were also measured. The detection of nitric oxide by means of diaminofluoresceins is much more efficient and faster in living cells than in PBS solutions, even though the conversion to the fluorescent form is a multi-step reaction.

show abstract

“…8 Recently, researchers have developed a variety of exogenous NO donors, including thionitrosothiols, metal nitric oxide complexes, polyamines, diazendioates, etc., which respond to various stimuli and specifically release NO to reduce systemic toxicity. [9][10][11][12][13] For instance, Fang et al loaded DOX and a NO donor (S-nitrosothiol) into mesoporous silica (MSN) to construct DN@MSN nanoparticles. The results showed that the loaded NO donor can activate matrix metalloproteinases (MMPs), enhance the penetration and accumulation of DN@MSN and DOX in tumors, thereby significantly improving the antitumor efficacy.…”

Section: Introductionmentioning

confidence: 99%

A nano-catalyst promoting endogenous NO production to enhance chemotherapy efficacy by vascular normalization

Wang

Feng

Sun

et al. 2022

Mater. Chem. Front.

View full text Add to dashboard Cite

show abstract

Anticancer potential of nitric oxide (NO) in neuroblastoma treatment

Abstract: S-Nitrosoglutathione (GSNO) reduces cell viability, inhibits cell division, and induces cell cycle arrest and apoptosis in neuroblastoma cells.

Cited by 10 publications

References 41 publications

Anticancer Impact of Nitric Oxide (NO) and NO Combination with SMYD-3 Inhibitor on Breast Carcinomas

Anticancer Impact of Nitric Oxide (NO) and NO Combination with SMYD-3 Inhibitor on Breast Carcinomas

Nanomolar Nitric Oxide Concentrations in Living Cells Measured by Means of Fluorescence Correlation Spectroscopy

A nano-catalyst promoting endogenous NO production to enhance chemotherapy efficacy by vascular normalization

Contact Info

Product

Resources

About